Israeli Innovation Authority Leads $70 Million AI Consortium for Personalized Medicine
The Israeli Innovation Authority is spearheading a consortium investing approximately 70 million shekels to develop next-generation artificial intelligence applications in biology, drug discovery, and personalized medicine. The initiative brings together leading companies such as Nvidia, Teva, Sheba Medical Center, CytoReason, TerraCyte, and MeMed, alongside top researchers from the Weizmann Institute, Technion, and Ben-Gurion University.
The consortium aims to tackle a key challenge in computational biology: representing, processing, and integrating complex, multimodal, and dynamic biological data. To address this, it will develop a shared technological infrastructure featuring two core components. The first, Bio Tokens, will provide a unified representation layer for diverse biological data types. The second, Factory Model, will be a platform enabling the development, integration, execution, and accessibility of AI-based biological models. Together, these components will connect molecular, cellular, dynamic, and clinical data within a single computational framework, serving industry, academia, and healthcare.
Scientific leadership is provided by Professors Eran Segal and Nir Yosef from the Weizmann Institute, Professor Shay Shnaor from the Technion, and Professor Asaf Zviran from Ben-Gurion University. The collaboration is designed as a pre-competitive R&D infrastructure to benefit the entire Israeli life sciences ecosystem.
Initial applications will focus on predicting responses to oncology treatments, assessing immune system activity, forecasting drug hypersensitivity, supporting medical decisions in sepsis, evaluating transplant rejection, autoimmune diseases, and drug discovery.
